Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (389)	6/5/2003 6:48:22 AM
From: Icebrg	Read Replies (1) \| Respond to of 1840

Active Biotech's TTS-CD2 results as presented at ASCO. I think the results were less than impressive. The company will shelve this product and move on with the next generation product TTS-CD3, which is supposed to induce less immune responses and cause fewer side-effects. A phase II study of ABR-214936 (anatumomab mafenatox) tumor targeted superantigen (TTS) therapy in patients with advanced renal cell carcinoma (RCC) asco.org Phase II study of amotumoab maferatox (ABR) 214936 in adv NSCLC: Results of a multi-institutional open label repeat dose trial with pt-specific dose escalation asco.org Tumor targeted superantigen therapy in advanced non-small cell lung cancer: A phase I dose escalation study of ABR-214936, anatumomab mafenatox. asco.org In the short term only SAIK-MS (Multiple Sclerosis, phase II) will be of interest in Active's pipeline. Erik